<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">13446</article-id><article-id pub-id-type="doi">10.7554/eLife.13446</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology and Stem Cells</subject></subj-group></article-categories><title-group><article-title>Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-47688"><name><surname>Walia</surname><given-names>Mannu K</given-names></name><aff><institution>St. Vincent's Institute of Medical Research</institution>, <addr-line><named-content content-type="city">Fitzroy</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-47689"><name><surname>Ho</surname><given-names>Patricia MW</given-names></name><aff><institution>St. Vincent's Institute of Medical Research</institution>, <addr-line><named-content content-type="city">Fitzroy</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-47690"><name><surname>Taylor</surname><given-names>Scott</given-names></name><aff><institution>St. Vincent's Institute of Medical Research</institution>, <addr-line><named-content content-type="city">Fitzroy</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-47691"><name><surname>Ng</surname><given-names>Alvin JM</given-names></name><aff><institution>St. Vincent's Institute of Medical Research</institution>, <addr-line><named-content content-type="city">Fitzroy</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-47692"><name><surname>Gupte</surname><given-names>Ankita</given-names></name><aff><institution>St. Vincent's Institute of Medical Research</institution>, <addr-line><named-content content-type="city">Fitzroy</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-47693"><name><surname>Chalk</surname><given-names>Alistair M</given-names></name><aff><institution>St. Vincent's Institute of Medical Research</institution>, <addr-line><named-content content-type="city">Fitzroy</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-28225"><name><surname>Zannettino</surname><given-names>Andrew CW</given-names></name><aff><institution content-type="dept">Myeloma Research Laboratory, School of Medicine, Faculty of Health Sciences</institution>, <institution>University of Adelaide</institution>, <addr-line><named-content content-type="city">Adelaide</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-47694"><name><surname>Martin</surname><given-names>T John</given-names></name><aff><institution>St. Vincent's Institute of Medical Research</institution>, <addr-line><named-content content-type="city">Fitzroy</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-41219"><name><surname>Walkley</surname><given-names>Carl R</given-names></name><aff><institution>St. Vincent's Institute of Medical Research</institution>, <addr-line><named-content content-type="city">Fitzroy</named-content></addr-line>, <country>Australia</country><email>cwalkley@svi.edu.au</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1062"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Reviewing editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>12</day><month>04</month><year>2016</year></pub-date><elocation-id>e13446</elocation-id><supplementary-material><ext-link xlink:href="elife-13446-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>02</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>08</day><month>04</month><year>2016</year></date></history><permissions><copyright-statement>Â© 2016, Walia et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Walia et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Mutations in the P53 pathway are a hallmark of human cancer. The identification of pathways upon which p53-deficient cells depend could reveal therapeutic targets that may spare normal cells with intact p53. In contrast to P53 point mutations in other cancer, complete loss of P53 is a frequent event in osteosarcoma (OS), the most common cancer of bone. The consequences of p53 loss for osteoblastic cells and OS development are poorly understood. Here we use murine OS models to demonstrate that elevated <italic>Pthlh</italic> (<italic>Pthrp</italic>), cAMP levels and signalling via CREB1 are characteristic of both p53-deficient osteoblasts and OS. Normal osteoblasts survive depletion of both PTHrP and CREB1. In contrast, p53-deficient osteoblasts and OS depend upon continuous activation of this pathway and undergo proliferation arrest and apoptosis in the absence of PTHrP or CREB1. Our results identify the PTHrP-cAMP-CREB1 axis as an attractive pathway for therapeutic inhibition in OS.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Health and Medical Research Council, Australia and the Bureau of Animal Welfare, Victorian Government . All of the animals were handled according to approved institutional animal care and use committee (Animal Ethics Committee) protocols (#017/15) of the St. Vincent's Hospital Melbourne.</p></fn><fn fn-type="other"><p>Human subjects: Primary human osteoblasts were isolated from bone marrow aspirates from the posterior iliac crest of de-identified healthy human adult donors with informed consent and consent to publish (IMVS/SA Pathology normal bone marrow donor program RAH#940911a, Adelaide, South Australia).</p></fn></fn-group></back></article>